More reads
- Gilead CEO to testify before a House committee about pricing for its HIV prevention pill. (STAT)
- Short sellers bet on opioid fallout sinking drug companies’ stocks. (Wall Street Journal)
- Bluebird Bio's pricing plan worries one biotech analyst. Here's why. (Barron's)
- Vertex to pay startup Kymera $70 million in R&D deal. (STAT Plus)
.png)
No hay comentarios:
Publicar un comentario